[1]
|
Martinaud, C., Gaillard, T., Graffin, B., et al. (2008) Vertebral Osteomyelitis Due to Streptococcus agalactiae ST-17. Annales de Biologie Clinique, 66, 87-89.
|
[2]
|
Piccinelli, G., Biscaro, V., Gargiulo, F., Caruso, A. and De Francesco, M.A. (2015) Characterization and Antibiotic Susceptibility of Streptococcus agalactiae Isolates Causing Urinary Tract Infections. Infection, Genetics and Evolution, 34, 1-6. https://doi.org/10.1016/j.meegid.2015.07.001
|
[3]
|
中华人民共和国国家卫生和计划生育委员会. 抗菌药物临床应用指导原则[M]. 北京: 人民卫生出版社, 2015: 68.
|
[4]
|
国家卫生计生委医政医管局, 国家卫生计生委合理用药专家委员会. 国家抗微生物治疗指南[M]. 第2版. 北京: 人民卫生出版社, 2018: 92-101.
|
[5]
|
Graziani, A.L., Lawson, L.A., Gibson, G.A., Steinberg, M.A. and MacGregor, R.R. (1988) Vancomycin Concentrations in Infected and Noninfected Human Bone. Antimicrobial Agents and Chemotherapy, 32, 1320-1322. https://doi.org/10.1128/aac.32.9.1320
|
[6]
|
Bolukaoto, J.Y., Monyama, C.M., Chukwu, M.O., Lekala, S.M., Nchabeleng, M., Maloba, M.R.B., et al. (2015) Antibiotic Resistance of Streptococcus agalactiae Isolated from Pregnant Women in Garankuwa, South Africa. BMC Research Notes, 8, Article No. 364. https://doi.org/10.1186/s13104-015-1328-0
|
[7]
|
Barros, R.R., Barros, C.C., Kegele, F.C.O., Francisca da S. N. Soares, M. and de Paula, G.R. (2024) Macrolide Resistance among Streptococcus agalactiae during COVID-19 Public Health Emergency in Brazil. Brazilian Journal of Microbiology, 55, 1445-1449. https://doi.org/10.1007/s42770-024-01356-4
|
[8]
|
Gonzalez Moreno, M., Trampuz, A. and Di Luca, M. (2017) Synergistic Antibiotic Activity against Planktonic and Biofilm-Embedded Streptococcus agalactiae, Streptococcus pyogenes and Streptococcus oralis. Journal of Antimicrobial Chemotherapy, 72, 3085-3092. https://doi.org/10.1093/jac/dkx265
|
[9]
|
Livorsi, D.J., Daver, N.G., Atmar, R.L., Shelburne, S.A., White, A.C. and Musher, D.M. (2008) Outcomes of Treatment for Hematogenous Staphylococcus aureus Vertebral Osteomyelitis in the MRSA Era. Journal of Infection, 57, 128-131. https://doi.org/10.1016/j.jinf.2008.04.012
|
[10]
|
Amari, E.B., Vuagnat, A., Stern, R., et al. (2004) High versus Standard Dose Vancomycin for Osteomyelitis. Scandinavian Journal of Infectious Diseases, 36, 712-717.
|
[11]
|
Moenster, R.P., Linneman, T.W., Finnegan, P.M. and McDonald, J.R. (2012) Daptomycin Compared to Vancomycin for the Treatment of Osteomyelitis: A Single-Center, Retrospective Cohort Study. Clinical Therapeutics, 34, 1521-1527. https://doi.org/10.1016/j.clinthera.2012.06.013
|
[12]
|
Boselli, E., Breilh, D., Debon, R., Duflo, F., Bel, J.C., Saux, M.C., et al. (2002) Penetration of Piperacillin/Tazobactam (4 G/500 mg) into Synovial Tissue. Journal of Chemotherapy, 14, 54-58. https://doi.org/10.1179/joc.2002.14.1.54
|
[13]
|
Perry, C.M. and Markham, A. (1999) Piperacillin/Tazobactam: An Updated Review of Its Use in the Treatment of Bacterial Infections. Drugs, 57, 805-843. https://doi.org/10.2165/00003495-199957050-00017
|
[14]
|
Moenster, R.P., Linneman, T.W., Finnegan, P.M., Hand, S., Thomas, Z. and McDonald, J.R. (2014) Acute Renal Failure Associated with Vancomycin and Β-Lactams for the Treatment of Osteomyelitis in Diabetics: Piperacillin-Tazobactam as Compared with Cefepime. Clinical Microbiology and Infection, 20, O384-O389. https://doi.org/10.1111/1469-0691.12410
|
[15]
|
华春珍, 俞蕙, 庄捷秋, 等. 2011至2015年181例儿童无乳链球菌血流感染多中心研究[J]. 中华儿科杂志, 2016, 54(8): 577-581.
|
[16]
|
Bauer, T.M., Pippert, H. and Zimmerli, W. (1997) Vertebral Osteomyelitis Caused by Group B Streptococci (Streptococcus agalactiae) Secondary to Urinary Tract Infection. European Journal of Clinical Microbiology & Infectious Diseases, 16, 244-246. https://doi.org/10.1007/bf01709590
|
[17]
|
Solı́s-Garcia del Pozo, J., Martinez-Alfaro, E., Abad, L. and Solera, J. (2000) Vertebral Osteomyelitis Caused by Streptococcus agalactiae. Journal of Infection, 41, 84-90. https://doi.org/10.1053/jinf.2000.0694
|